Menu

2015 Top 10 Innovations: Enter Today!

Submissions are officially open for this year’s Top 10 Innovations contest.

Apr 13, 2015
The Scientist

It’s time to submit a product or methodology to The Scientist’s 2015 Top 10 Innovations competition.

In previous years our judges have singled out 3-D organ models, next-gen sequencers, cutting-edge microscopes, fluorescent RNA detection probes, and futuristic genetic-modification technologies—all products that continue to revolutionize research and push biology’s boundaries. (See the 2014 Top 10 Innovations winners.)

You can enter a laboratory tool, technology, software, methodology, or product for a chance to win a coveted spot in The Scientist’s Top 10 Innovations of 2015, as ranked and rated by an expert panel of independent judges. This year, we’ve opened the submissions process to include not only product managers, developers, or marketers who manufacture exciting new life-science tools, but also to users of innovative products. So whether you make them, sell them, or use them in the lab, enter today to see how your favorite new life-science innovation ranks among this year’s crop.

Past winners can attest to the fact that entering the contest is well worth the few minutes it takes to fill out the submission form.

Tilmann Buerckstuemmer, director of R&D at Horizon Genomics, told The Scientist that winning second place in the 2013 Top 10 Innovations contest for the company’s X-Man reporter kits was great for business. “Following the announcement [that we had won], our cell line sales increased quite significantly,” he said. “So we definitively feel it was worth applying!”

And Stephen Ripp, chief operating officer of 490 Biotech, reported a similar uptick for his firm’s humanized bacterial luciferase, which took sixth place in the 2013 competition. “We saw the number of requests for our autobioluminescent cell lines more than double after the publication of the Top 10 Innovations list, and our product is now integrated into research programs at major universities and government labs around the world,” Ripp said. “We were thrilled to be chosen as a Top 10 Innovation and cannot thank The Scientist enough for the exposure it has provided us.”

Submissions will be accepted until 12:00 a.m. EDT September 15. The winners will be announced on December 1, with a feature-length article highlighting this year’s Top 10 winners in that month’s issue of The Scientist.

Read the complete rules and submit your innovation today!

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.